Compare Heron Therapeutics Inc (HRTX) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Direxion Daily S&P 500 Bull 3X Shares trades at $297.65 (market cap $7.36B). The key difference: Direxion Daily S&P 500 Bull 3X Shares is far larger — about 108.2× Heron Therapeutics Inc's market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| HRTX | SPXL | |
|---|---|---|
Market Cap | $68.01M | $7.36B |
Volume | 1,891,941 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.49 | $301.38 |
52-Week Low | $0.27 | $170.20 |
Typical Hold Time | 35 Days | 32 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
SPXL trades at $296.84, down 0.79% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF maintains neutral oscillator signals while approaching key resistance at $299. Recent market sentiment reflects mixed outlooks for S&P 500 performance amid earnings growth concerns and seasonal patterns.
The leveraged ETF's performance remains tied to S&P 500 movements, with Wall Street projecting potential upside but facing headwinds from expected earnings growth slowdown. Key risks include market concentration in top holdings and geopolitical uncertainties affecting broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
